Referred to the House Committee on Financial Services.
Email me when HR 9102 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HR 9102. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The BINSA Act adds biotechnology—pharmaceuticals, biologics, and related therapeutic research—to the list of technologies that can be restricted or reported under the Defense Production Act. It requires the Treasury to define the biotech sector and to focus on licensing, joint‑venture and equity deals with Chinese firms. The goal is to prevent U.S. capital and intellectual property from strengthening China’s biotech capabilities, which lawmakers view as a strategic risk.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HR 9102
3 free questions a day, no accountSponsors
- Rep. Moolenaar, John R. [R-MI-2] (R) · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HR 9102 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HR 9102 freeOr ask your AI assistant about HR 9102 directly:
Add to Claude, ChatGPT or Cursor